diagnosis of APS is suspected. Hydroxychloroquine could be a valid treatment in CNS manifestations in patients with APS.

**Funding Source(s):** None

---

**THERAPEUTIC AND RENAL PROTECTIVE EFFECTS OF DZ2002, A REVERSIBLE SAHH INHIBITOR, ON LUPUS-PRONE NZB×NZW F1 MICE**

1Shijun He*, 2Zemin Lin, 3Wei Tang, 1Jiaping Zuo. 1Shanghai Institute of Materia Medica, Chinese Academy of Sciences; 2Shanghai Institute of Materia Medica

10.1136/lupus-2019-lsm.67

**Background** Glomerulonephritis is one of the major complications and causes of death in systemic lupus erythematosus (SLE). DZ2002 is a reversible S-adenosyl-l-homocysteine hydrolase (SAHH) inhibitor with potent therapeutic activity against lupus nephritis in mice. However, the molecular events underlying the renal protective effects of DZ2002 remained unclear. This study is designed to uncover the molecular mechanisms of DZ2002 on glomerulonephritis of lupus-prone mice.

**Methods** Female NZB/W F1 mice were treated orally with DZ2002, and the proteinuria level and body weight were monitored. After the mice were euthanized, serum biochemical parameters and renal damage were determined. Spleenocytes of NZB/W F1 mice were isolated for *ex vivo* study. Toll-like receptor (TLR)-stimulated murine bone marrow-derived dendritic cells (BMDCs) were used for *in vitro* study. The LC-MS-based label-free quantitative (LFQ) proteomic approach was applied to analyze the kidney tissue samples from the NZB/W F1 mice treated with DZ2002 or vehicle. KEGG pathway enrichment and direct protein-protein interaction (PPI) network analyses were used to map the pathways in which the significantly changed proteins (SCPs) involved. The selected proteins from proteomic analysis were validated by Western blot analysis and immunohistochemistry in the kidney tissues.

**Results** Treatment of the mice with DZ2002 significantly attenuated the progression of glomerulonephritis and improved the overall health. The improvement was accompanied by decreased levels of nephritogenic anti-dsDNA antibodies, serum IL-17, IL-23p19 and TGF-. DZ2002 also significantly suppressed TLR agonists-stimulated up-regulation in IL-6 and IL-23p19 production in murine BMDCs, and prevented Th17 differentiation and suppressed IL-17 secretion by the T cells in a BMDC-T cell co-culture system. Pathway analysis of proteomic data revealed that 13 SCPs were involved in tight junction and focal adhesion process. Further protein expression validation demonstrated that DZ2002 treated NZB/W F1 mice exhibited down-regulation of -actinin-4 and integrin-linked kinase (ILK), as well as the restoration of 1-integrin activation in kidney tissues compared with vehicle treated ones.

**Conclusions** Our study demonstrated that DZ2002 effectively ameliorates lupus syndrome in NZB/W F1 mice by regulating TLR signaling-mediated antigen presenting cell (APC) responses. Alongside of attenuating glomerular immune complexes deposition and impeding pathologic lymphocytes polarization in SLE, the renal protective effects of DZ2002 may partly attributed to stabilization of the actin cytoskeleton and maintenance of podocyte numbers, in turn, are effective to improve proteinuria and kidney function in lupus nephritis.

**Funding Source(s):** The National Basic Research Program of China (973 Program) (grant number: 2014CB541906); and the National Nature Science Foundation of China (grant number: 81402939)

---

**ADMINISTRATION OF ARTEMISININ ANALOGUE SM934 AMELIORATES DISEASE MANIFESTATION IN LUPUS-PRONE MICE VIA RESTORING IMMUNE HOMEOSTASIS**

1Zemin Lin*, 2Jiaping Zuo, 3Shijun He, 4Wei Tang. 1Shanghai Institute of Materia Medica, Chinese Academy of Sciences; 2Shanghai Institute of Materia Medica

10.1136/lupus-2019-lsm.68

**Background** Artemisinin and its derivatives were reported to possess strong regulatory effects on inflammation and autoimmune diseases. This study was designed to examine the therapeutic effects and underlying mechanisms of SM934, a water-soluble artemisinin analogue, on lupus-prone mice.

**Methods** For MRL/lpr mice: *In vivo*, the preventative or therapeutic effects of SM934 in MRL/lpr mice were investigated. *Ex vivo*, the mechanisms of treatment were explored according to the immunologic correlates of disease. Impacts of SM934 on Toll-like receptor (TLR)-triggered B cell responses were evaluated. In *vitro*, the effects of SM934 on the activation and differentiation of CD4 + T cells were examined. For NZB/W F1 mice: *In vivo*, the lupus-prone mice were treated with SM934 for 3 or 6 months respectively to investigate the effect on clinical manifestations and immunological correlates. To further explore the mechanisms of SM934, ovalbumin (OVA)-immunized or interferon (IFN)–elicited C57BL/6 mice were used.

**Results** *In vivo*, SM934 treatment significantly prolonged the life-span of MRL/lpr mice, ameliorated the lymphadenopathy, decreased the levels of serum anti-nuclear antibodies (ANAs) and the pathogenic cytokines IFN-, IL-6, IL-10 and IL-21, and reduced the proportion of double negative T cells. Treatment with SM934 significantly delayed the progression of glomerulonephritis and improved the survival of NZB/W F1 mice. Clinical improvement was accompanied with decreased anti-dsDNA Abs and serum interleukin IL-17. In addition, SM934 treatment promoted the IL-10 production from macrophages of NZB/W F1 mice, OVA-immunized C57BL/6 mice and IFN-elicited C57BL/6 mice. *Ex vivo*, SM934 treatment elevated the percentage of Treg cells, inhibited the development of Th1 and Th17 cells. Moreover, SM934 suppressed the TLR-triggered activation and proliferation of B cells. *In vitro*, SM934 inhibited the differentiation of Th1 and Th17 cells as well as TLR-associated B-cell activation and plasma cell differentiation. SM934 enhanced IL-10 production from primary macrophages stimulated with IFN-.

**Conclusions** Taken together, these results demonstrated that the artemisinin analogue SM934 exerted significant therapeutic benefits in lupus-prone mice, by inhibiting both the pathogenic helper T cell development and responses, enhancing anti-inflammatory cytokine IL-10 production and suppressing plasma cell formation. These properties of SM934 might contributed to the restoration of the immune homeostasis in lupus-susceptible mice, and thus cast a light on a novel strategy for lupus treatment.

**Funding Source(s):** National Science Fair Committee (NSFC), China (No. 81273524, 81322049), National Science and Technology Major Project 2019-YFC1700805, National Basic Research Program of China (973 Program) (grant number: 2014CB541906); and the National Nature Science Foundation of China (grant number: 81402939).